Recombinant Human MDC1 Protein，His

MDC1 (mediator of DNA damage checkpoint 1) is a pivotal protein involved in the cellular response to DNA damage, particularly in the context of DNA double-strand breaks (DSBs). Understanding its role is crucial as DSBs can lead to genomic instability and are implicated in various cancers. MDC1 acts as a molecular scaffold, recruiting other proteins to the sites of DNA damage, thus facilitating the DNA damage response (DDR) pathway. The research on recombinant MDC1 proteins has gained momentum due to their potential applications in cancer therapeutics and diagnostics. By expressing and purifying MDC1 in vitro, researchers can explore its structural and functional properties in greater detail, allowing for the identification of interactions with other DDR proteins. Furthermore, recombinant MDC1 can be utilized to develop assays to screen for inhibitors or modulating agents that might enhance the efficacy of DNA damage-inducing therapies, such as radiotherapy and certain chemotherapeutics. There is also an interest in understanding how post-translational modifications of MDC1 affect its function and interactions, which could reveal new avenues for therapeutic intervention. Consequently, the study of MDC1 recombinant proteins is not only significant for basic science in understanding the DNA damage response but also has the potential to inform clinical strategies for tackling cancer and other diseases linked to genomic instability.